Mechanisms for the bone anabolic effect of parathyroid hormone treatment in humans

References

• el-Hajj FG, Chen CJ, Rivkees SA, Marynick SP, Stock J, Pallotta JA, Brown EM. Calcium-dependent release of N-terminal fragments and intact immunoreactive parathyroid hormone by human pathological parathyroid tissue in vitro. J Clin Endocrinol Metab 1989;69:860–7.
   PubMed Web of Science ®Google Scholar
• Schwarz P, Sorensen HA, McNair P, Transbol I. Cica-clamp technique: a method for quantifying parathyroid hormone secretion: a sequential citrate and calcium clamp study. Eur J Clin Invest 1993;23:546–53.
   PubMed Web of Science ®Google Scholar
• Schwarz P. Dose response dependency in regulation of acute PTH (1-84) release and suppression in normal humans: a citrate and calcium infusion study. Scand J Clin Lab Invest 1993;53:601–5.
   PubMed Web of Science ®Google Scholar
• Schwarz P, Sorensen HA, Transbol I. Inter-relations between the calcium set-points of Parfitt and Brown in primary hyperparathyroidism: a sequential citrate and calcium clamp study. Eur J Clin Invest 1994;24:553–8.
   PubMed Web of Science ®Google Scholar
• Momsen G, Schwarz P. A mathematical/physiological model of parathyroid hormone secretion in response to blood-ionized calcium lowering in vivo. Scand J Clin Lab Invest 1997;57:381–94.
   PubMed Web of Science ®Google Scholar
• Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993;366:575–80.
   PubMed Web of Science ®Google Scholar
• Ejersted C, Andreassen TT, Hauge EM, Melsen F, Oxlund H. Parathyroid hormone (1-34) increases vertebral bone mass, compressive strength, and quality in old rats. Bone 1995;17:507–11.
   PubMed Web of Science ®Google Scholar
• Arita S, Ikeda S, Sakai A, Okimoto N, Akahoshi S, Nagashima M, Nishida A, Ito M, Nakamura T. Human parathyroid hormone (1-34) increases mass and structure of the cortical shell, with resultant increase in lumbar bone strength, in ovariectomized rats. J Bone Miner Metab 2004;22:530–40.
   PubMed Web of Science ®Google Scholar
• Bradenburg VM, Floege J. Adynamic bone disease – bone and beyond. NDT Plus. 2008;3:135–47.
   Google Scholar
• Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, Ghaye AF, Beckers A. Hormonal and biochemical normalization and tumor shrinkage induced by anti-parathyroid hormone immunotherapy in a patient with metastatic parathyroid cracinoma. JCEM 2004;89:3413–20.
   PubMed Web of Science ®Google Scholar
• Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006;7:113–21.
   PubMed Web of Science ®Google Scholar
• Mohan S, Kutilek S, Zhang C, Shen HG, Kodama Y, Srivastava AK,Wergedal JE, Beamer WG, Baylinik DJ. Comparison of bone formation responses to parathyroid hormone(1-34), (1-31), and (2-34) in mice. Bone 2000;27:471–8.
   PubMed Web of Science ®Google Scholar
• Rosenblatt M, Segre GV, Tyler GA, Shepard GL, Nussbaum SL, PottsJR JT. Identification of a receptor-binding region in parathyroid hormone. Endocrinology 1980;107:545–50.
   PubMed Web of Science ®Google Scholar
• Gardella TJ, Axelrod D, Rubin D, Keutmann HT, PottsJr JT, Kronenberg HM, Nussbaum SR. Mutational analysis of the receptor-activating region of human parathyroid hormone. J Biol Chem 1991;266:13141–6.
   PubMed Web of Science ®Google Scholar
• Murrills R. Parathyroid hormone and bone cells. Clin Rev Bone Min Metab 2006;4:233–57.
   Google Scholar
• Dempster DW, Hughes-Begos CE, Plavetic-Chee K, Brandao-Burch A, Cosman F, Nieves J, Neubort S, Lu SS, Iida-Klein A, Arnett T, Lindsay R. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem 2005;95:139–48.
   PubMed Web of Science ®Google Scholar
• Lee K, Deeds JD, Chiba S, Un-No M, Bond AT, Segre GV. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 1994;134:441–50.
   PubMed Web of Science ®Google Scholar
• Cranney A, Papaioannou A, Zytaruk N, Hanley D, Adachi J, Goltzman D, Murray T, Hodsman A. Parathyroid hormone for the treatment of osteoporosis: a systematic review. CMAJ 2006;175:52–9.
   PubMed Web of Science ®Google Scholar
• Yang D, Singh R, Divieti P, Guo J, Bouxsein ML, Bringhurst FR. Contributions of parathyroid hormone (PTH)/PTH-related peptide receptor signaling pathways to the anabolic effect of PTH on bone. Bone 2007;40:1453–61.
   PubMed Web of Science ®Google Scholar
• Seelentag WK, Mermod JJ, Montesano R, Vassalli P. Additive effects of interleukin 1 and tumour necrosis factor-alpha on the accumulation of the three granulocyte and macrophage colony-stimulating factor mRNAs in human endothelial cells. EMBO J 1987;6:2261–5.
   PubMed Web of Science ®Google Scholar
• Jimi E, Shuto T, Koga T. Macrophage colony-stimulating factor and interleukin-1 alpha maintain the survival of osteoclast-like cells. Endocrinology 1995;136:808–11.
   PubMed Web of Science ®Google Scholar
• Huang JC, Sakata T, Pfleger LL, Bencsik M, Halloran BP, Bikle DD, Nissenson RA. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res 2004; 19:235–44.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597–602.
   PubMed Web of Science ®Google Scholar
• Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem 2003;89:180–90.
   PubMed Web of Science ®Google Scholar
• Lee S-K, Lorenzo J. Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation. Endocrinology 1999;140:3552–61.
   PubMed Web of Science ®Google Scholar
• Kanzawa M, Sugimoto T, Kanatani M, Chihara K. Involvement of osteoprotegerin/osteoclastogenesis inhibitory factor in the stimulation of osteoclast formation by parathyroid hormone in mouse bone cells. Eur J Endocrinol 2000;142:661–4.
   PubMed Web of Science ®Google Scholar
• McCabe LR, Kockx M, Lian J, Stein J, Stein G. Selective expression of fos- and jun-related genes during osteoblast proliferation and differentiation. Exp Cell Res 1995;218:255–62.
   PubMed Web of Science ®Google Scholar
• Grigoriadis AE, Wang ZQ, Wagner EF. Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet 1995;11:436–41.
   PubMed Web of Science ®Google Scholar
• McCauley LK, Koh AJ, Beecher CA, Rosol TJ. Proto-oncogene c-fos is transcriptionally regulated by parathyroid hormone (PTH) and PTH-related protein in a cyclic adenosine monophosphate-dependent manner in osteoblastic cells. Endocrinology 1997;138:5427–33.
   PubMed Web of Science ®Google Scholar
• Karaplis AC, Goltzman D. PTH and PTHrP effects on the skeleton. Rev Endocr Metab Disord 2000;1:331–41.
   PubMedGoogle Scholar
• Leaffer D, Sweeney M, Kellerman LA, Avnur Z, Krstenansky JL, Vickery BH, Caulfield JP. Modulation of osteogenic cell ultrastructure by RS-23581, an analog of human parathyroid hormone (PTH)-related peptide-(1-34), and bovine PTH-(1-34). Endocrinology 1995;136:3624–31.
   PubMed Web of Science ®Google Scholar
• Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 1995;136:3632–8.
   PubMed Web of Science ®Google Scholar
• Davies J, Chambers TJ. Parathyroid hormone activates adhesion in bone marrow stromal precursor cells. J Endocrinol 2004;180:505–13.
   PubMed Web of Science ®Google Scholar
• Watson P, Lazowski D, Han V, Fraher L, Steer B, Hodsman A. Parathyroid hormone restores bone mass and enhances osteoblast insulin-like growth factor I gene expression in ovariectomized rats. Bone 1995;16:357–65.
   PubMed Web of Science ®Google Scholar
• McCarthy TL, Centrella M, Canalis E. Parathyroid hormone enhances the transcript and polypeptide levels of insulin-like growth factor I in osteoblast-enriched cultures from fetal rat bone. Endocrinology 1989;124:1247–53.
   PubMed Web of Science ®Google Scholar
• Linkhart TA, Mohan S. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 1989;125:1484–91.
   PubMed Web of Science ®Google Scholar
• Miyakoshi N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S. Evidence that anabolic effects of PTH on bone require IGF-I in growing mice. Endocrinology 2001;142:4349–56.
   PubMed Web of Science ®Google Scholar
• Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GD, Marcus R, Eriksen EF. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. JBMR 2006;21:855–64.
   Google Scholar
• Canalis E. Effect of insulin like growth factor I on DNA and protein synthesis in cultured rat calvaria. J Clin Invest 1980;66:709–19.
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003;278:50259–72.
   PubMed Web of Science ®Google Scholar
• Krishnan V, Moore TL, Ma YL, Helvering LM, Frolik CA, Valasek KM, Ducy P, Geiser AG. Parathyroid hormone bone anabolic action requires Cbfa1/Runx2-dependent signaling. Mol Endocrinol 2003;17:423–35.
   PubMed Web of Science ®Google Scholar
• Grey A, Chen Q, Xu X, Callon K, Cornish J. Parallel phosphatidylinositol-3 kinase and p42/44 mitogen-activated protein kinase signaling pathways subserve the mitogenic and antiapoptotic actions of insulin-like growth factor I in osteoblastic cells. Endocrinology 2003;144:4886–93.
   PubMed Web of Science ®Google Scholar
• Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999;104:439–46.
   PubMed Web of Science ®Google Scholar
• Jilka RL. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone 2007;40:1434–46.
   PubMed Web of Science ®Google Scholar
• Komarova SV. Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 2005;146:3589–95.
   PubMed Web of Science ®Google Scholar
• Gowen M, Stroup GB, Dodds RA, James IE, Votta BJ, Smith BR, Bhatnagar PK, Lago AM, Callahan JF, DelMar EG, Miller MA, Nemeth EF, Fox J. Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J Clin Invest 2000;105:1595–1604.
   PubMed Web of Science ®Google Scholar
• Liu F, Kohlmeier S, Wang CY. Wnt signaling and skeletal development. Cell Signal 2008;20:999–1009.
   PubMed Web of Science ®Google Scholar
• Piters E, Boudin E, Van Hul W. Wnt signaling: a win for bone. Arch Biochem Biophys 2008;473:112–6.
   PubMed Web of Science ®Google Scholar
• Holmen, SL, Zylstra CR, Mukherjee A, Sigler RE, Faugere MC, Bouxsein ML, Deng L, Clemens TL, Williams BO. Essential role of beta-catenin in postnatal bone acquisition. J Biol Chem 2005;280:21162–8.
   PubMed Web of Science ®Google Scholar
• Kramer I, Halleux C, Keller H, Pegurri M, Gooi JH, Weber PB, Feng JQ, Bonewald LF, Kneissel M. Osteocyte Wnt/-catenin signaling is required for normal bone homeostasis. Mol Cell 2010;30:3071–85.
   Web of Science ®Google Scholar
• Day TF, Guo X, Garrett-Beal L, Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell 2005;8:739–50.
   PubMed Web of Science ®Google Scholar
• Hill TP, Spater D, Taketo MM, Birchmeier W, Hartmann C. Canonical Wnt/beta-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev Cell 2005;8:727–38.
   PubMed Web of Science ®Google Scholar
• Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The cell: molecular biology of the cell, 5th ed. Garland Science, New York, NY, USA, 2008.
   Google Scholar
• Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K, Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins WS, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black GMC, Boles RG, Boon RM, Borrone C, Brunner HG, Carle GF, Dallapiccola B, Paepe A, Floege B, Halfhide ML, Hall B, Hennekam RC, Hirose T, Jans A, Jüppner H, Kim CA, Keppler-Noreuil K, Kohlschuetter A, LaCombe D, Lambert M, Lemyre E, Letteboer T, Peltonen L, Ramesar RS, Romanengo M, Somer H, Steichen-Gersdorf E, Steinmann B, Sullivan B, Superti-Furga A, Swoboda W, Boogaard MJ, Van Hul W, Vikkula M, Votruba M, Zabel B, Garcia T, Baron R. Olsen BR, Warman ML. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 2001;107:513–23.
   PubMed Web of Science ®Google Scholar
• Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu D, Insogna K, Lifton RP. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 2002;346:1513–21
   PubMed Web of Science ®Google Scholar
• Li J, Sarosi I, Russell C, Pretorius CJ, Asuncion F, Grisanti M, Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL, W. Simonet S, Bolon B, Qian X, Shalhoub V, Ominsky MS, Ke HZ, Li X Richards WG. Dkk1-mediated inhibition of Wnt signalling in bone results in osteopenia. Bone 2006;39:754–66.
   PubMed Web of Science ®Google Scholar
• van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, Hamarsma H, Papapoulos SE, ten Dijke P, Löwik CW. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199:805–14.
   PubMed Web of Science ®Google Scholar
• Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone 2005;37:148–58.
   PubMed Web of Science ®Google Scholar
• Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. JBMR 2005;20:177–84.
   Google Scholar